

## PATENT ASSIGNMENT

Electronic Version v1.1  
 Stylesheet Version v1.1


SUBMISSION TYPE:	NEW ASSIGNMENT
NATURE OF CONVEYANCE:	ASSIGNMENT
CONVEYING PARTY DATA	
Name	Execution Date
4325231 Canada Inc.	07/10/2007
RECEIVING PARTY DATA	
Name:	Genesense Technologies Inc.
Street Address:	2 Meridian Road
City:	Toronto
State/Country:	CANADA
Postal Code:	M9W 4Z7
PROPERTY NUMBERS Total: 1	
Property Type	Number
Application Number:	12976122
CORRESPONDENCE DATA	
Fax Number:	(312)775-8100
Email:	lwilliamson@mcandrews-ip.com
<i>Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent via US Mail.</i>	
Correspondent Name:	McAndrews Held & Malloy, Ltd.
Address Line 1:	500 West Madison Street
Address Line 2:	34th Floor
Address Line 4:	Chicago, ILLINOIS 60661
ATTORNEY DOCKET NUMBER:	16526US02
NAME OF SUBMITTER:	Michael B. Harlin
Total Attachments: 6 source=4325231 Canada - Genesense Technologies Inc. - Assignment 2#page1.tif source=4325231 Canada - Genesense Technologies Inc. - Assignment 2#page2.tif source=4325231 Canada - Genesense Technologies Inc. - Assignment 2#page3.tif source=4325231 Canada - Genesense Technologies Inc. - Assignment 2#page4.tif source=4325231 Canada - Genesense Technologies Inc. - Assignment 2#page5.tif source=4325231 Canada - Genesense Technologies Inc. - Assignment 2#page6.tif	

CH \$40.00 12976122

CANADA )

Province of Ontario )

On this 10<sup>TH</sup> day of JULY, 2007, before me, Vanessa Grant, a Notary Public in and for the Province of Ontario, personally appeared **Aiping Young**, personally known to me or proven on the basis of satisfactory evidence to be the person whose name is subscribed to the within instrument, and acknowledged to me that she executed the same in her capacity, and that by her signature on the instrument the person, or the entity upon behalf of which the person acted, executed the instrument.



\_\_\_\_\_  
A NOTARY PUBLIC IN AND FOR THE  
PROVINCE OF ONTARIO

## ASSIGNMENT OF INVENTION


In consideration of One (\$1.00) Dollar and other good and valuable consideration, the receipt and sufficiency of which is hereby acknowledged, we, **4325231 CANADA INC.** (hereinafter "the Assignor"), do hereby sell, assign and transfer to **GENESENSE TECHNOLOGIES INC.** (hereinafter "the Assignee"), all our right, title and interest throughout the world in and to (1) the inventions relating to and described and/or claimed in the patent applications and patents listed in Schedule A; (2) all improvements, including but not limited to modifications, additions, substitutions, derivatives, and deletions to said invention(s); (3) the patent applications and patents listed in Schedule A and national phase applications thereof; (4) all other applications for Letters Patent in any country throughout the world for said invention(s) and improvements, including but not limited to all divisional, continuation, continuation-in-part, renewal, reissue, and substitute applications; (5) any Letters Patent which may issue from any of said applications as exemplified in (3) and (4) above in any country throughout the world; (6) all Convention or Treaty rights derived from any of said applications, including without limitation, all rights of priority throughout the world in and to said applications; and (7) the full and complete right to file applications for Letters Patent in the name of the Assignee, or in our name at the Assignee's election, on said invention(s) and improvements in all countries throughout the world.

For said consideration, the Assignor agrees, upon the request and at the expense of the Assignee, its successors and assigns, to execute any and all divisional, continuation, continuation-in-part, reissue and substitute applications for said invention(s) and improvements, and acknowledge and agree that all rights therein shall vest in the Assignee, its successors and assigns, whereby said Letters Patent will be held and enjoyed by said Assignee, its successors and assigns, to the full end of the term for which said Letters Patent will be granted, as fully and entirely as the same would have been held and enjoyed by the undersigned if this assignment had not been made. In addition, the Assignor will, at the request of the Assignee, execute any and all documents required by the Assignee to fully and properly vest the aforementioned rights in the Assignee.

The undersigned hereby grants to the firm of **MBM & CO.** whose full post office address is P.O. Box 809, Station B, Ottawa, Ontario, Canada, K1P 5P9, the power to insert on this assignment any further information and/or correct any clerical error in the information pertaining to the referenced applications and patents, which may be necessary or desirable in order to comply with the patent legislation for recordation of this document.

**FOR THE ASSIGNOR:**


SIGNED at Toronto, Ontario, Canada, this 10<sup>TH</sup> day of JULY, 2007.

Signature: 

Name: AIPING YOUNG

Title: PRESIDENT & CEO  
**4325231 CANADA INC.**  
**2 Meridian Road, Toronto, Ontario M9W 4Z7, Canada**


I was personally present and did see AIPING YOUNG duly sign and execute the above assignment.

  
(Signature of witness)

VANESSA GRANT  
(Name of witness)

**FOR THE ASSIGNEE:**


SIGNED at Toronto, Ontario, Canada, this 10<sup>TH</sup> day of JULY, 2007.

Signature: 

Name: AIPING YOUNG

Title: PRESIDENT & CEO  
**GENESENSE TECHNOLOGIES INC.**  
**2 Meridian Road, Toronto, Ontario M9W 4Z7, Canada**

I was personally present and did see AIPING YOUNG duly sign and execute the above assignment.

  
(Signature of witness)

VANESSA GRANT  
(Name of witness)

**Schedule A****Immunomodulating Compositions from Bile  
(Virulizin)**

Country	Filed	Serial #	Patent #
AUSTRALIA	9/9/1994	97242/98	732816
CANADA	9/9/1994	2,171,281	2,171,281
CHINA	9/9/1994	94194002	135158
EUROPE (Germany, Spain, France, Italy, Great Britain)	9/9/1994	94926737.1	717631
HONG KONG	9/9/1994	98107139	HK1007922
JAPAN	9/9/1994	508370/95	
SOUTH KOREA	9/9/1994	96-701198	260110
MEXICO	9/9/1994	9406945	212,218
NEW ZEALAND	9/9/1994	273,258	273258
UNITED STATES	9/9/1994	08/612,921	6,280,774
UNITED STATES	1/7/2000	09/479,835	6,551,623
UNITED STATES	12/13/2006	11/637,921	

**IMMUNOMODULATING COMPOSITIONS FROM BILE FOR THE TREATMENT OF  
IMMUNE SYSTEM DISORDERS  
(Virulizin)**

Country	Filed	Serial #	Patent #
AUSTRALIA	3/13/1996	48739/96	711294
CANADA	3/13/1996	2,215,339	2,215,339
BRAZIL	3/13/1996	P19607967	
JAPAN	3/13/1996	8(1996)-527137	
MEXICO	3/13/1996	977111	
SINGAPORE	3/13/1996	9705689-9	50147

**IMMUNOMODULATING COMPOSITIONS FOR TREATMENT OF IMMUNE SYSTEM  
DISORDERS  
(Virulizin)**

Country	Filed	Serial #	Patent #
UNITED STATES	1/17/2001	09/764,010	6,596,319

**IMMUNOMODULATING COMPOSITIONS FOR THE TREATMENT OF VIRAL DISORDERS  
(Virulizin)**

Country	Filed	Serial #	Patent #
SOUTH AFRICA	7/13/1998	986,224	986,224

**COMBINATION PREPARATION OF A BIOLOGICAL RESPONSE MODIFIER AND AN ANTICANCER AGENT AND USES THEREOF**

(Virulizin in combination with chemotherapy)

Country	Filed	Serial #
CANADA	11/8/2001	2,428,145
EUROPE	11/8/2001	1983364.9
HONG KONG	11/8/2001	4100981.7
UNITED STATES	11/8/2001	11/247,026

**2,4,5-TRISUBSTITUTED IMIDAZOLES AND THEIR USE AS ANTI-MICROBIAL AGENTS (ML-220)**

Country	Filed	Serial #
AUSTRALIA	8/19/2003	2003257329
BRAZIL	8/19/2003	PI0313763-5
CANADA	8/19/2003	2,496,241
CHINA	8/19/2003	3824355.5
EUROPE	8/19/2003	3787546.5
HONG KONG	10/24/2005	5109435.9
JAPAN	8/19/2003	2004-526206
MEXICO	8/19/2003	2005/002040
UNITED STATES	8/19/2003	10/525,690

**ARYL IMIDAZOLES AND THEIR USE AS ANTICANCER AGENTS (ML-133)**

Country	Filed	Serial #
AUSTRALIA	11/15/2004	20044289539
CANADA	11/15/2004	2,545,942
EUROPE	11/15/2004	4799154.2
HONG KONG	11/15/2004	5103616.3
JAPAN	11/15/2004	2006-539085
UNITED STATES	11/15/2004	10/579,149

**2-INDOLYL IMIDAZO [4,5-D] PHENANTHROLINE DERIVATIVES AND USES THEREOF IN THE TREATMENT OF CANCER (LT-253 AND LT-297)**

Country	Filed	Serial #
UNITED STATES	3/31/2006	60/787,526
INTERNATIONAL	5/25/2006	PCT/IB06/51675

**USE OF 2-INDOLYL IMIDAZO[4,5-D]PHENANTHROLINE DERIVATIVES IN THE TREATMENT OF INFLAMMATION AND ALLERGY**

<b>Country</b>	<b>Filed</b>	<b>Serial #</b>
UNITED STATES	11/29/2006	60/867,678

**2-INDOLYL IMIDAZO[4,5-D]PHENANTHROLINE DERIVATIVES AND USES THEREOF IN COMBINATION THERAPY FOR THE TREATMENT OF CANCER**

<b>Country</b>	<b>Filed</b>	<b>Serial #</b>
UNITED STATES	11/29/2006	60/867,672

**USE OF INTERLEUKIN 17E FOR THE TREATMENT OF CANCER**

<b>Country</b>	<b>Filed</b>	<b>Serial #</b>
INTERNATIONAL	3/8/2006	PCT/CA06/00311